Ingrid Wertz

Ingrid E. Wertz is a co-founder and the CEO of Lyterian Therapeutics. She obtained her undergraduate degree in Molecular and Cellular Biology from the University of California at Berkeley and performed her graduate research at Genentech via an NIH Biotechnology Training Grant from U.C. Davis, for which she received a Harold M. Weintraub Graduate Student Award. Ingrid received her M.D. from Washington University in St. Louis as a Medical Scientist Training Program fellow and, following her graduate studies, joined Genentech where she ran a basic science research lab, co-initiated and led the Genentech Degrader Platform, and contributed to drug discovery programs, including those leading to the discovery of the FDA-approved BCL-2 inhibitor venetoclax, the PI3K inhibitor taselesib, and the selective estrogen receptor degrader giredistrant that is currently in Phase 3 trials. Following Genentech, Ingrid joined Bristol Myers Squibb as the Executive Director of the Protein Homeostasis Center of Excellence, and subsequently co-founded Lyterian Therapeutics. Lyterian is focused on strategies to identify and harness endogenous protein homeostasis machinery for therapeutic benefit.